Rethinking brain health
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative conditions.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative conditions.
This gives us the potential to revolutionise how people think about brain health.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Our products
Pharma/Biotech
- Measures you can trust
- Get more from your MRI
- Run targeted, more efficient clinical trials
- Efficient use of technology across multiple conditions
Clinical
- Supporting patient care
- Helping clinicians in their diagnosis
- Differential patterns of brain changes
- Accurately tracking changes
- Proactive brain health
Latest news
Fierce Lifes Sciences Category - Oxford Brain Diagnostics is Finalist in Digital Health Awards 2026
Forge’s Fierce Life Sciences today announced the finalists of the 2026 Fierce Life Science Innovation Awards and Fierce Healthcare Innovation Awards, recognizing organizations developing breakthrough technologies, solutions and approaches that are advancing the life sciences and healthcare industries. Oxford Brain Diagnostics is selected finalist for Digital Health Solutions Awards 2026.
New Study Shows Cortical Disarray Measurement (CDM®) Can Reflect Microscopic Patterns of Pathology in Frontotemporal Dementia
Oxford Brain Diagnostics (OBD), a pioneer in quantitative brain biology, today announced new research demonstrating that its Cortical Disarray Measurement (CDM®) technology reflected the distribution of autopsy-confirmed pathology in people with frontotemporal lobar degeneration (FTLD). FTLD is the underlying disease process in frontotemporal dementia (FTD), the most common form of dementia in people under age 60.
Oxford Brain Diagnostics Appoints Healthcare AI Executive Jieun Choe as Chief Executive Officer and Board Director
Oxford, United Kingdom – September 15, 2026— Oxford Brain Diagnostics (OBD), a pioneer in quantitative brain biology, today announced the appointment of Jieun Choe as Chief Executive Officer and a member of its Board of Directors.
Oxford Brain Diagnostics Advances Vision for Measuring Brain Health and Neurodegenerative Disease with Five New Studies at AAIC 2026
New findings demonstrate the potential of OBD's MRI-based Cortical Disarray Measurement (CDM®) technology to support patient identification, disease characterization, treatment monitoring, and therapeutic development across Alzheimer's disease
